Eudaimonia Partners’s Novavax NVAX Stock Holding History

Eudaimonia Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5	Closed	-$1K	–	1018
2021 Q1	$1K	Buy	+5	New	+$996	﹤0.01%	1567

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Eudaimonia Partners's NVAX Position: Q2 2021 in Review

Eudaimonia Partners sold out of Novavax (NVAX) in Q2 2021, closing a stake of 5 shares — an estimated $1K sold.

Eudaimonia Partners first reported a position in NVAX in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 407 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

Eudaimonia Partners reported no remaining Novavax position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 5 Novavax shares in Q2 2021, an estimated $1K.
Eudaimonia Partners first reported a position in Novavax in Q1 2021 and held it in 1 quarter.
Eudaimonia Partners's Novavax position peaked at $1K in Q1 2021.
407 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.